Laura E McCoubrey, Nidhi Seegobin, Nannapat Sangfuang, Frédéric Moens, Hans Duyvejonck, Eline Declerck, Arno Dierick, Massimo Marzorati, Abdul W Basit
Successful treatment of ulcerative colitis (UC) is highly dependent on several parameters, including dosing regimen and the ability to deliver drugs to the disease site. In this study two strategies for delivering mesalazine (5-aminosalicylic acid, 5-ASA) to the colon were compared in an advanced in vitro model of the human gastrointestinal (GI) tract, the SHIME® system. Herein, a prodrug strategy employing bacteria-mediated drug release (sulfasalazine, Azulfidine®) was evaluated alongside a formulation strategy that utilised pH and bacteria-mediated release (5-ASA, Octasa® 1600 mg)...
April 8, 2024: Journal of Controlled Release